These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 17171704)

  • 1. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
    Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
    Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
    Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
    Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
    Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
    Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic prostate cancer in an asymptomatic patient with an initial prostate-specific antigen (PSA) serum concentration of 21,380 ng/ml.
    Persec Z; Persec J; Sović T; Romic Z; Bosnar Herak M; Hrgovic Z
    Onkologie; 2010; 33(3):110-2. PubMed ID: 20215802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
    BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
    Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O
    Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
    Zhu H; Roehl KA; Antenor JA; Catalona WJ
    Urology; 2005 Sep; 66(3):547-51. PubMed ID: 16140075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
    Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
    Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of prostate-specific antigen in the diagnosis and treatment of prostatic adenocarcinoma].
    Stamey TA
    Urologe A; 1990 Mar; 29(2):52-64. PubMed ID: 1691883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
    Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
    Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic local recurrence of prostate carcinoma after radiation therapy.
    Leibovici D; Lee AK; Cheung RM; Spiess PE; Kuban DA; Rosser CJ; Shen Y; Yang Y; Chichakli R; Pisters LL
    Cancer; 2005 May; 103(10):2060-6. PubMed ID: 15822114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen.
    Beekman K; Morris M; Slovin S; Heller G; Wilton A; Bianco F; Scardino PT; Scher HI
    Urology; 2005 May; 65(5):947-52. PubMed ID: 15882729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of androgen independence in metastatic prostate cancer.
    Sim HG; Lau WK; Cheng CW
    BJU Int; 2004 Jun; 93(9):1221-4. PubMed ID: 15180610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.
    Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
    Cancer; 2003 Dec; 98(11):2362-7. PubMed ID: 14635070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
    Aus G
    Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
    J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.